Albireo Pharma Inc (NASDAQ:ALBO) insider Ronald Harold Wilfred Cooper bought 788 shares of Albireo Pharma stock in a transaction that occurred on Tuesday, August 14th. The stock was bought at an average cost of $31.85 per share, for a total transaction of $25,097.80. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Albireo Pharma stock traded up $0.44 during trading hours on Friday, reaching $30.17. 26,989 shares of the company’s stock were exchanged, compared to its average volume of 75,904. Albireo Pharma Inc has a 52-week low of $20.25 and a 52-week high of $39.87. The firm has a market cap of $372.59 million, a PE ratio of -9.53 and a beta of 1.23.

Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($1.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.24). The business had revenue of $0.73 million during the quarter, compared to the consensus estimate of $2.00 million. analysts forecast that Albireo Pharma Inc will post -3.36 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of ALBO. BlackRock Inc. lifted its stake in shares of Albireo Pharma by 582.8% during the 2nd quarter. BlackRock Inc. now owns 524,276 shares of the biopharmaceutical company’s stock worth $18,611,000 after purchasing an additional 447,496 shares during the period. Federated Investors Inc. PA purchased a new position in shares of Albireo Pharma during the 1st quarter worth $10,094,000. Artal Group S.A. lifted its stake in shares of Albireo Pharma by 82.6% during the 1st quarter. Artal Group S.A. now owns 547,841 shares of the biopharmaceutical company’s stock worth $17,843,000 after purchasing an additional 247,841 shares during the period. BVF Inc. IL purchased a new position in shares of Albireo Pharma during the 1st quarter worth $7,328,000. Finally, Millennium Management LLC lifted its stake in shares of Albireo Pharma by 234.0% during the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after purchasing an additional 109,017 shares during the period. 55.97% of the stock is currently owned by institutional investors.

A number of equities research analysts recently issued reports on ALBO shares. Zacks Investment Research raised Albireo Pharma from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a research note on Tuesday, July 24th. Jefferies Financial Group started coverage on Albireo Pharma in a research note on Friday, April 20th. They issued a “buy” rating and a $50.00 target price on the stock. BidaskClub lowered Albireo Pharma from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 18th. Cowen reaffirmed a “buy” rating on shares of Albireo Pharma in a research note on Wednesday, August 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $69.00 target price on shares of Albireo Pharma in a research note on Tuesday, June 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $59.40.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Featured Story: Stock Symbols and CUSIP Explained

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.